Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore, Maryland 21224, United States.
Neurobiology of Addiction Section, National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Baltimore, Maryland 21224, United States.
ACS Chem Neurosci. 2022 Jul 6;13(13):1832-1834. doi: 10.1021/acschemneuro.2c00326. Epub 2022 Jun 24.
Despite the high prevalence and negative consequences associated with alcohol use disorder (AUD), currently available pharmacotherapies are limited in number and efficacy. Several neuroendocrine pathways have been identified and are under investigation as potential pharmacotherapeutic targets for AUD. Here, we present the promise of the mineralocorticoid receptor (MR) as a novel target and discuss associations between the aldosterone/MR system and AUD, the effects of MR antagonism on alcohol consumption, and the underlying neurobiology of these effects.
尽管酒精使用障碍（AUD）的患病率很高，且会带来负面影响，但目前可用的药物疗法数量有限，疗效也有限。已经确定了几种神经内分泌途径，并正在作为 AUD 的潜在药物治疗靶点进行研究。在这里，我们提出了作为新型靶点的盐皮质激素受体（MR）的前景，并讨论了醛固酮/MR 系统与 AUD 之间的关联、MR 拮抗作用对酒精消费的影响以及这些影响的潜在神经生物学机制。
